What is the current stock price of MiNK Therapeutics, Inc. (INKT)?

As of the latest market data, MiNK Therapeutics, Inc. (INKT) is trading at $11.04. The stock has seen a loss of -3.75% today.

Does MiNK Therapeutics, Inc. (INKT) pay a dividend?

Based on current data, MiNK Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of MiNK Therapeutics, Inc.?

The current market capitalization of MiNK Therapeutics, Inc. (INKT) is approximately unavailable.

INKT

MiNK Therapeutics, Inc.·Healthcare

11.04

3.749%(−0.43)

Market Closed

11.49

4.076%(+0.45)

After Hours

Last Updated: — ET

52W L: $6.3452W H: $76.00

INKT NEWS

defenseworld.net

6d ago

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold” by Brokerages

MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given

globenewswire.com

Apr 3

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, evaluating agent-797, MiNK's allo-iNKT cell therapy, in combination with botensilimab (BOT) and balstilimab (BAL), will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA.

globenewswire.com

Apr 1

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 occurring May 15-20, 2026 in Orlando, Florida.

seekingalpha.com

Mar 31

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 31

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025.

defenseworld.net

Mar 27

MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short Interest

MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) was the target of a significant growth in short interest in March. As of March 13th, there was short interest totaling 149,702 shares, a growth of 303.4% from the February 26th total of 37,106 shares. Based on an average daily trading volume, of 1,570,416 shares, the days-to-cover

Company Profile

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-10-15

Beta

0.35

Websiteminktherapeutics.com↗